Related Experiment Videos
Gaucher disease: pathological mechanisms and modern management
Marina Jmoudiak1, Anthony H Futerman
1Department of Biological Chemistry, Weizmann Institute of Science, Rehovot, Israel.
British Journal of Haematology
|April 9, 2005
Summary
Gaucher disease, a lysosomal storage disorder, results from defective acid-beta-glucosidase activity, causing glucosylceramide accumulation. This review examines pathological mechanisms and evaluates current and developing therapies.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Gaucher disease is the most common lysosomal storage disorder.
- It stems from deficient acid-beta-glucosidase (GlcCerase) activity, leading to glucosylceramide (GlcCer) accumulation.
- Weak genotype-phenotype correlations exist, with limited understanding of downstream biochemical effects.
Purpose of the Study:
- To discuss the pathological mechanisms of Gaucher disease.
- To evaluate the advantages and disadvantages of existing therapies.
- To review emerging treatment strategies.
Main Methods:
- Literature review of pathological mechanisms.
- Analysis of clinical course and treatment outcomes.
- Evaluation of enzyme replacement and substrate reduction therapies.
Main Results:
- GlcCer accumulation primarily affects macrophage lineage cells.
- Clinical manifestations of Gaucher disease are well-documented.
- Enzyme replacement therapy is an established treatment; substrate reduction therapy is newly marketed.
Conclusions:
- Understanding downstream biochemical changes is crucial for Gaucher disease.
- Existing therapies offer benefits but also have limitations.
- Further development of novel therapeutic approaches is ongoing.